Changed plasma prolactin levels after etoperidone and placebo.
A neuroendocrinological study was carried out by evaluating plasma prolactin levels after etoperidone i.m. (100 mg) and placebo. Fourteen male inpatients (mean age: 35.36 +/- 11.7 years) with chronic schizophrenia were selected for the study, whose aim was to improve interpretation of the pharmacological activity of etoperidone. The results suggest that etoperidone plays the role of an atypical psychotropic drug since it does not affect prolactin levels. In addition, the drug is devoid of anticholinergic effects, which facilitates its prospective clinical use for medium-term and long-term therapy.
D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D010919:Placebos; D011388:Prolactin / Q000097:blood*; D012559:Schizophrenia / Q000097:blood; D014196:Trazodone / Q000009:adverse effects* / Q000031:analogs & derivatives
D000928:Antidepressive Agents; D010879:Piperazines; D010919:Placebos; D011388:Prolactin; C013528:etoperidone; D014196:Trazodone